NCT02320669View on ClinicalTrials.gov

Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Congenital Heart Defects
Interventions
DRUG

Triostat

Bolus of Triiodothyronine followed by infusion for 48 hours

DRUG

Placebo

Bolus of Placebo followed by infusion for 48 hours

Trial Locations (3)

90027

Los Angeles Children's Hospital, Los Angeles

94304

Lucille Packard Children's Hospital, Palo Alto

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER

NCT02320669 - Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter